Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation
Reduced-intensity cord blood transplantation (RI-CBT) is an attractive alternative for elderly patients and patients with organ impairment who do not have appropriate human leukocyte antigen (HLA)-identical bone marrow or peripheral blood stem cell donors. However, graft rejection may occur after RI-CBT and cause serious difficulties for these patients who require urgent administration of immunosuppressive drugs followed by infusion of another unit of cord blood. We and the other group previously reported the outcome of patients who had received a second CBT for graft rejection using a preparative regimen consisting of fludarabine and melphalan with or without total body irradiation. 1, 2 Of the five patients, four achieved primary engraftment. However, three of these patients ultimately died of transplant-related mortality. All five patients developed grades 3-5 regimen-related toxicities (RRTs). These data suggest that RRTs are a major obstacle for successful second CBT after an initial graft rejection and that an optimal RI preparative regimen should be developed. In this paper, we describe successful second RI-CBT using fludarabine and cyclophosphamide without total body irradiation in a patient with initial graft rejection.
A 59-year-old woman received RI-CBT owing to chemorefractory de novo acute myelomonocytic leukemia. She had no available HLA-identical family donors and, owing to disease progression, could not wait for a match from the Japan Marrow Donor Program. The transplant procedures used in this patient are shown in Table 1 . The RRTs were evaluated using the Common Terminology Criteria for Adverse Events, version 3.0. 3 Chimerism was assessed using polymerase chain reaction as described previously. 4 Peripheral cytopenia persisted after RI-CBT. The bone marrow examination on day 20 revealed a few hematopoietic cells and 65% donor chimerism. On day 28, graft rejection was diagnosed based on severe marrow hypoplasia and complete host chimerism of bone marrow cells.
The patient received a second RI-CBT as treatment for the initial graft rejection, 35 days after the initial CBT. The preparative regimen for the second RI-CBT consisted of 125 mg/m 2 fludarabine (day À6 to À2, 25 mg/m 2 /day) and 60 mg/kg cyclophosphamide on day À6 (Table 1) . Prophylaxis for graft-versus-host disease (GVHD) consisted of 0.02 mg/kg tacrolimus and short-term methotrexate (day 1, 10 mg/m 2 /day; days 3 and 6, 7 mg/m 2 /day; Table 1 ). On day 19 after the second RI-CBT, primary engraftment of neutrophils (4500/ml) and complete donor chimerism were achieved. The patient had a generalized convulsion on day 23, and was diagnosed as having human herpesvirus 6 (HHV-6) encephalitis; however, the encephalitis resolved spontaneously. On day 23, the patient was found to have a small nodular mass in the apex of one lung on computed tomography scan, which was diagnosed as an invasive fungal infection based on established diagnostic criteria. 5 The mass responded to antifungal therapy. The patient did not develop acute GVHD. She developed grade 3 gastrointestinal (anorexia) and infectious (febrile neutropenia) RRTs (Table 1 ). The patient's anorexia was managed with appropriate fluid replacement and subsided spontaneously; the febrile neutropenia responded to antibiotics. The patient did not develop mucosal RRT. The bone marrow examination done on day 97 revealed normal hematopoiesis and complete donor chimerism of the marrow cells.
This report indicates that the combination of fludarabine and cyclophosphamide could be a feasible preparative regimen for use with second CBT in patients who develop graft rejection following an initial RI-CBT. Remarkably, mucosal RRT was grade 0. In contrast, more severe RRTs have been reported in patients who received fludarabine and melphalan for the second CBT.
1,2 The removal of melphalan from the regimen might have contributed to the reduction of mucosal toxicity. Mucosal damage caused by preparative regimens allows the transition from colonization to blood stream infection 6 and increases the risk of thrombocytopenic microangiopathy, 7 which have been reported to be significant problems after RI-CBT. The success of the second RI-CBT in our patient might be mainly attributed to the use of the fludarabine and cyclophosphamide regimen.
Physicians have been concerned that fludarabine 125 mg/m 2 and cyclophosphamide 60 mg/kg may not provide enough immunosuppression to suppress residual host immune cells. Barker et al.
8 previously reported delayed achievement of complete donor chimerism in patients who received a preparative regimen containing fludarabine 125 mg/m 2 and cyclophosphamide 50 mg/kg. In contrast, our patient achieved neutrophil engraftment and complete donor chimerism on day 19. In our patient, the immunosuppression of the preparative regimen given for the first RI-CBT may have contributed to the rapid engraftment and achievement of complete donor chimerism, even though it did not ensure engraftment after the first RI-CBT. GVHD tends to be severe after the second transplantation. Therefore, intensive GVHD prophylaxis, including tacrolimus and methotrexate, was used based on the favorable results seen in our recent retrospective study. Our patient did not develop post-CBT immune reactions. The intensive prophylaxis that was given may also have contributed to the favorable clinical course after the second CBT.
An important factor that affects the prognosis is the occurrence of opportunistic infections during prolonged neutropenia. Our patient's neutropenic period lasted 44 days; however, she did not develop fatal infectious complications. This might have been partly due to the mild mucosal RRT. We did not use additional steroids for post-CBT immunoreactions, which might have increased the risk of infection. This also may have been involved in the patient's favorable outcome.
We report a successful second RI-CBT using fludarabine and cyclophosphamide as a preparative regimen following initial graft rejection. To improve the management of graft rejection, some issues still need to be solved. For example, prolonged neutropenia is a major problem. The rapid diagnosis of graft rejection and re-transplantation is important. Graft failure was diagnosed on day 28 in our patient based on the chimerism analysis of bone marrow cells. However, monitoring of chimerism in the peripheral blood on a weekly basis might have helped to establish the diagnosis more rapidly. Use of two cord units for the second CBT might also be worth investigating, since rapid engraftment has been reported with CBT using two cord units. 
